Literature DB >> 26754533

The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Erin M Swaney1, Anuja Chattopadhyay1, Irina Abecassis1, Elizabeth A Rush1, Robert L Redner1.   

Abstract

The variant acute promyelocytic leukemia (APL) translocation t(5;17)(q35;q21) fuses the N-terminus of nucleophosmin (NPM1) to the retinoic acid receptor alpha (RARA). We found that ectopic NPM1-RARA expression decreased TP53 protein levels in target cells. NPM1-RARA impaired TP53-dependent transcription. Cells expressing NPM1-RARA were more resistant to apoptotic stimuli. This work identifies the TP53 tumor suppressor as a novel target through which NPM1-RARA impacts leukemogenesis, and confirms the importance of impairment of TP53 in establishment of the APL phenotype.

Entities:  

Keywords:  Acute promyelocytic leukemia; NPM1-RARA; TP53; apoptosis; nucleophosmin

Mesh:

Substances:

Year:  2016        PMID: 26754533      PMCID: PMC5023140          DOI: 10.3109/10428194.2015.1124992

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  33 in total

1.  A new quantitative assay for cytochrome c release in apoptotic cells.

Authors:  N J Waterhouse; J A Trapani
Journal:  Cell Death Differ       Date:  2003-07       Impact factor: 15.828

2.  The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.

Authors:  C W So; S Dong; C K So; G X Cheng; Q H Huang; S J Chen; L C Chan
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

3.  The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.

Authors:  Takeshi Kondo; Akio Mori; Stephanie Darmanin; Satoshi Hashino; Junji Tanaka; Masahiro Asaka
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

4.  TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.

Authors:  Yirui Chen; Shouyun Li; Chunlin Zhou; Chengwen Li; Kun Ru; Qing Rao; Haiyan Xing; Zheng Tian; Kejing Tang; Yingchang Mi; Baohong Wang; Min Wang; Jianxiang Wang
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

5.  NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

Authors:  Anuja Chattopadhyay; Irina Abecassis; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2015-10-05

6.  BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

Authors:  Yukiya Yamamoto; Sachiko Tsuzuki; Motohiro Tsuzuki; Kousuke Handa; Yoko Inaguma; Nobuhiko Emi
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

7.  The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.

Authors:  Alberto Catalano; Mark A Dawson; Karthiga Somana; Stephen Opat; Anthony Schwarer; Lynda J Campbell; Harry Iland
Journal:  Blood       Date:  2007-08-21       Impact factor: 22.113

8.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

Authors:  R L Redner; E A Rush; S Faas; W A Rudert; S J Corey
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

9.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

10.  Nucleophosmin regulates the stability and transcriptional activity of p53.

Authors:  Emanuela Colombo; Jean-Christophe Marine; Davide Danovi; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Nat Cell Biol       Date:  2002-07       Impact factor: 28.824

View more
  2 in total

Review 1.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

2.  Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.

Authors:  Qianqian Huang; Tao Wang; Yan Xiong; Liping Qu; Qiaozhi Yin; Wenjun Zou
Journal:  Chin Herb Med       Date:  2021-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.